-
公开(公告)号:ES2399427T3
公开(公告)日:2013-04-01
申请号:ES04780990
申请日:2004-08-10
Applicant: ARRAY BIOPHARMA INC
Inventor: WALLACE ELI , TOPALOV GEORGE , LYSSIKATOS JOSEPH , BUCKMELTER ALEXANDRE , ZHAO QIAN
IPC: A61K31/51 , A61K31/517 , A61K31/535 , C07D239/82 , C07D239/94 , C07D401/12 , C07D403/00 , C07D413/12 , C07D413/14 , C07D417/14 , C07D498/04 , C07D498/08
Abstract: Compuesto que incluye enantiómeros resueltos, diastereoisómeros, solvatos y sales farmacéuticamenteaceptables de los mismos, comprendiendo dicho compuesto la fórmula I: donde A está unido al menos a uno de los carbonos en las posiciones 5, 6, 7 u 8 del anillo bicíclico y donde elanillo bicíclico no está sustituido o está sustituido con uno o dos grupos R3 independientes; X es N o C-CN; A es Z; R1 es una fracción arilo o heteroarilo sustituida o no sustituida, monocíclica o bicíclica; R2 es H; R3 es hidrógeno u -OR6. **Fórmula**
-
公开(公告)号:BRPI0610863A2
公开(公告)日:2010-08-03
申请号:BRPI0610863
申请日:2006-05-18
Applicant: ARRAY BIOPHARMA INC
Inventor: LAIRD ELLEN , LYSSIKATOS JOSEPH P , WELCH MIKE , GRINA JONAS , HANSEN JOSH , NEWHOUSE BRAD , TOPALOV GEORGE
IPC: C07D487/04 , A61K31/4985 , A61P35/00
Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号:CA2535614C
公开(公告)日:2009-12-22
申请号:CA2535614
申请日:2004-08-10
Applicant: ARRAY BIOPHARMA INC
Inventor: BUCKMELTER ALEXANDRE , ZHAO QIAN , TOPALOV GEORGE , WALLACE ELI , LYSSIKATOS JOSEPH
IPC: C07D413/14 , A61K31/517 , A61P35/00 , C07D239/94 , C07D401/12 , C07D413/12 , C07D417/14 , C07D498/02 , C07D498/04 , C07D498/08
Abstract: This invention provides quinazoline analogs of Formula (I): where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula (I) as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
-
公开(公告)号:AU2003291394B2
公开(公告)日:2009-06-25
申请号:AU2003291394
申请日:2003-11-10
Applicant: ARRAY BIOPHARMA INC
Inventor: TOPALOV GEORGE , LYSSIKATOS JOSEPH P , WALLACE ELI , ZHAO QIAN
IPC: C07D239/94 , A61P31/18 , A61P35/00 , C07D401/12 , C07D403/12 , C07D405/04 , C07D417/14
Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Use of the compounds of the invention to manufacture therapeutic compositions for the treatment of hyperproliferative diseases in mammals is also disclosed.
-
公开(公告)号:AU2006247118A1
公开(公告)日:2006-11-23
申请号:AU2006247118
申请日:2006-05-18
Applicant: ARRAY BIOPHARMA INC
Inventor: NEWHOUSE BRAD , HANSEN JOSH , LYSSIKATOS JOSEPH P , GRINA JONAS , LAIRD ELLEN , WELCH MIKE , TOPALOV GEORGE
IPC: C07D487/04 , A61K31/4985 , A61P35/00
Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号:AU2004264937A1
公开(公告)日:2005-02-24
申请号:AU2004264937
申请日:2004-08-10
Applicant: ARRAY BIOPHARMA INC
Inventor: WALLACE ELI , ZHAO QIAN , BUCKMELTER ALEXANDRE , TOPALOV GEORGE , LYSSIKATOS JOSEPH
IPC: A61K31/51 , A61K31/517 , A61K31/535 , C07D239/82 , C07D239/94 , C07D401/12 , C07D403/00 , C07D413/12 , C07D413/14 , C07D417/14 , C07D498/04 , C07D498/08
Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
-
公开(公告)号:CY1113992T1
公开(公告)日:2016-07-27
申请号:CY131100122
申请日:2013-02-08
Applicant: ARRAY BIOPHARMA INC
Inventor: WALLACE ELI , TOPALOV GEORGE , LYSSIKATOS JOSEPH , BUCKMELTER ALEXANDRE , ZHAO QIAN
IPC: A61K31/51 , A61K31/517 , A61K31/535 , C07D239/82 , C07D239/94 , C07D401/12 , C07D403/00 , C07D413/12 , C07D413/14 , C07D417/14 , C07D498/04 , C07D498/08
Abstract: ΗπαρούσαεφεύρεσηπαρέχειανάλογακιναζολίνηςτουΤύπου (I): όπουτοΑ είναισυνδεδεμένομετουλάχιστονένααπότουςάνθρακεςστιςθέσεις 5, 6, 7 ή 8 θέσητουδικυκλικούδακτυλίου, καιο δακτύλιοςείναιυποκατεστημένοςμεέωςκαιδύοανεξάρτητες R 3 ομάδες. Ηεφεύρεσηπεριλαμβάνειεπίσηςμεθόδουςχρήσηςτωνενώσεωντουτύπου (I) ωςαναστολέωνυποδοχέωντύπου I τηςκινάσηςτηςτυροσίνηςκαιτηνθεραπευτικήαγωγήτωνυπερπολλαπλασιαστικώννόσωνόπωςο καρκίνος.
-
公开(公告)号:CO6251377A2
公开(公告)日:2011-02-21
申请号:CO09120874
申请日:2009-10-27
Applicant: ARRAY BIOPHARMA INC
Inventor: ALLEN SHELLEY , GRESCHUK JULIE MARIE , KALLAN NICHOLAS C , MARMSATER FREDRIK PEHR , MUNSON MARK , RIZZI JAMES , ROBINSON JOHN , SCHLACHTER STEPHEN , TOPALOV GEORGE , ZHAO QIAN , LYSSIKATOS JOSEPH
IPC: A61K31/33 , A61P35/00 , C07D471/04
Abstract: Se describen los compuestos de la Fórmula I: en los cuales A, B, R1, R1a, R2, R3, R4, R5 R6, R7 y R8 tienen los significados dados en la especificación, que son inhibidores de la tirosina receptora, útiles en el tratamiento de enfermedades mediadas por tirosina-cinasas receptoras de la clase 3 y de la clase 5. Los compuestos particulares de esta invención han sido también encontrados como inhibidores de Pim-1.
-
公开(公告)号:AR073079A1
公开(公告)日:2010-10-13
申请号:ARP090103170
申请日:2009-08-18
Applicant: ARRAY BIOPHARMA INC
Inventor: ALLEN SHELLEY , CELESTE LAURA L , MUNSON MARK , TOPALOV GEORGE , DELISLE ROBERT KIRK , DAVIS T GREGG , ZHAO QIAN , ROBINSON JOHN E , GRESCHUK JULIE MARIE , GROSS STEFAN D , HICKEN ERIK JAMES , JACKSON LEILA J , LYSSIKATOS JOSEPH P , KALLAN NICHOLAS , RAST BRYSON , SCHLACHTER STEPHEN T , WRIGHT A DALE , PHENEGER JED
IPC: C07D471/04 , A61K31/47 , A61K31/55 , A61P35/00 , A61P37/06
Abstract: Estos compuestos son inhibidores de tirosina de receptor utiles en el tratamiento de enfermedades asociadas con células inmunes, tales como enfermedades inflamatorias y autoinmunes. Se proveen además una composicion farmacéutica que los comprende y un método para su preparacion. Reivindicacion 1: Un compuesto de la formula general (1) o una sal farmacéuticamente aceptable de él, en donde: A es OR10 o NR11R12; B es H, F, Cl, ORa, alquilo C1-6NRbRc, alquilo C1-6OH, CH(OH)CH2OH o alquilo C1-4; R1 es H, F, Cl, Br, Me, ciclopropilo o CN; R1a, R2, R3 y R4 son independientemente H, F, Cl, Br, Me o CN; R5 y R7 son independientemente H, F, Me o CN; R6 es H, F, Me, Br, CN, ciclopropilo, fenilo, MeO- o MeOCH2CH2O-; R10 es H, hetCyc1, alquilo C1-3hetCyc1a, hetCyc2, (CR17R18)p(CR13R14)CH2NR15R16, -(CR17R18)p(CR13R14)CH2OH, alquilo C1-6, hetAr1, alquilo C1-3hetAr1a, o cicloalquilo C3-7 sustituido con NH2, NH-alquilo C1-6 o N(alquilo C1-6)2; R11 es H o alquilo C1-6; R12 es hetCyc3, alquilo C1-6NR15R16, C(O)alquilo C1-6NR15R16, alquilo C1-6NHC(O)O-alquilo C1-6, o cicloalquilo C4-7 optativamente sustituido con OH, NH2, NH-alquilo C1-6 o N(alquilo C1-6)2; R13 es H, alquilo C1-6, F o OH, y R14 es H, alquilo C1-6 o F, o R13 y R14 junto con el átomo de carbono al cual están unidos forman un anillo carbocíclico de 3-6 miembros; cada R15, R16, R17 y R18 es independientemente H o alquilo C1-6, o cada R15, R17, y R18 es independientemente H o alquilo C1-6 y R16 es H, alquilo C1-6, C(=O)CH2F, CH2CHF2 o CH2CF3; o NR15R16 forma un anillo heterocíclico de 5-6 miembros que tiene un primer heteroátomo del anillo que es N y que optativamente tiene un segundo heteroátomo del anillo que es N y O; hetCyc1, hetCyc1a y hetCyc3 son independientemente un heterociclo de 4-7 miembros que tiene un átomo del anillo de nitrogeno y optativamente sustituido con uno o más grupos R9, o hetCyc1 y hetCyc3 son independientemente un heterociclo de 4-7 miembros que tiene un átomo de N y optativamente sustituido con uno o más grupos R9, y hetCyc1a se selecciona de un morfolinilo y un anillo azacíclico de 4-7 miembros optativamente sustituido con uno o más grupos R9; cada R9 se selecciona independientemente de halogeno, alquilo C1-6, ciclopropilmetilo, bencilo, NRfRg, alquilo C1-6NRhRi, ORj, alquilo C1-6ORk, fluoroalquilo C1-6, C(O)NRmRn, alquilo C1-6C(O)NRpRq, y C(O)O-alquilo C1-6; hetCyc2 es un heterociclo de puente de 8 miembros que tiene un átomo de nitrogeno del anillo; hetAr1 y hetAr1a son independientemente un heteroarilo de 5 o 6 miembros que tiene 1-2 átomos de nitrogeno del anillo y optativamente sustituido con uno o más sustituyentes, que se seleccionan independientemente de F, Cl, Br, Me, ciclopropilo, CN, NH2, NH-alquilo C1-6 y N(alquilo C1-6)2; Ra es H, alquilo C1-6, alquilo C1-6-O-alquilo C1-6, o alquilo C1-6-O-cicloalquilo C3-6; cada Rb, Rf, Rg, Rh, Ri, Rk, Rm, Rp, y Rq se selecciona independientemente de H y alquilo C1-6; Rj es H, alquilo C1-6 o ciclopropilo; Rn es H, alquilo C1-6, -O-alquilo C1-6 o -O-cicloalquilo C3-6; y p es 0, 1 o 2.
-
公开(公告)号:NZ540092A
公开(公告)日:2007-06-29
申请号:NZ54009203
申请日:2003-11-10
Applicant: ARRAY BIOPHARMA INC
Inventor: WALLACE ELI , TOPALOV GEORGE , ZHAO QIAN , LYSSIKATOS JOSEPH P
IPC: A61P31/18 , A61P35/00 , C07D239/94 , C07D401/12 , C07D403/12 , C07D405/04 , C07D417/14 , A61K31/4706 , A61K31/517 , C07D215/42
Abstract: Disclosed is a compound of formula (I) wherein: At least one of the positions 6 or 7 of the quinazoline ring must be substituted by a group A and the remaining positions are optionally substituted by up to three R2 groups; X is N, CH or a C-CN group; R1 is independently aryl or heteroaryl substituted by at least one R6 group and optionally substituted by up to three R5 groups where R5 and R6 are as described in the specification; R2 represents H, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, optionally substituted as defined; and A is represented by formula (II) wherein: T represents alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl optionally substituted as defined; L is N or a CR4 group where R4 is as defined in the specification; Q is selected from CR3R11R12 or NR11R12 where R3 is the same as R2 above and R11 and R12 are as defined; D represents H, trifluoromethyl, difluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -SO2NR9R7, -C(O)R9, -OC(O)R9 or -C(O)NR7R9 optionally substituted as defined; and The remaining substituents are as defined in the specification. Compounds of the type discloser are EGFR and ErbB2 inhibitors useful in the treatment of hyperproliferative diseases.
-
-
-
-
-
-
-
-
-